NCT06791460View on ClinicalTrials.gov

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

February 14, 2028

Study Completion Date

February 14, 2030

Conditions
Ovarian Cancer Recurrent
Interventions
DRUG

Pegylated liposomal doxorubicin plus adebrelimab with mirabegron

Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle orally with daily mirabegron until intolerance or disease progression.

DRUG

Pegylated liposomal doxorubicin plus adebrelimab

Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle until intolerance or disease progression.

Trial Locations (1)

200090

RECRUITING

Obstetrics and Gynecology Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Obstetrics & Gynecology Hospital of Fudan University

OTHER